Link to Pubmed [PMID] – 26072415
Methods Mol. Biol. 2015;1317:327-39
The use of DNA vaccines requires pharmaceutical grade DNA that causes the immunization on the basis of a nucleic acid sequence that encodes the protein to be vaccinated against. This nucleic acid sequence can be a circular or linear plasmid, preferably a double stranded one and should not contain any other and especially not any “toxic” sequences. Sequences that are not desirable to be part of the DNA drug can be those deriving from the (typically) bacterial amplification system to produce the DNA vaccine. These could be those portions of a plasmid that are only used for controlling the bacterial replication of the plasmid or those used to select for the plasmid during cloning or even worse during production. After initial approaches to avoid the presence of these sequences in DNA vaccine plasmids with “mini-plasmids,” a significant improvement in product safety was obtained by use of minicircles-circular and ccc-supercoiled expression cassettes of the DNA vaccine. Initial results proofed their extremely high expression level and recent comparison of DNA vaccines based on either plasmid or minicircle DNA show successful vaccination against HBV in mice, as shown in this overview chapter.